AKAnvar Hassan Kaleeckal

Anvar Hassan Kaleeckal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anvar Hassan Kaleeckal has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study

    by Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Patrick Tang, Mohammad R Hasan, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Methods: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort). Results: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%–6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%–9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%–53.2%). The rVE was 26.9% (95% CI, −12.7%–53.4%) within <24 days, 51.8% (95% CI, 19.2%–71.2%) during Days 24–179, and 36.8% (95% CI, 0.9%–59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals. Conclusions: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.

  • Open Access

    Assessing the Impact of the Healthy Vaccinee Effect on COVID-19 Vaccine Effectiveness Estimates

    by Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: Health status influences uptake of COVID-19 vaccination, with vaccinated individuals generally being healthier than their unvaccinated counterparts. However, the extent to which this healthy vaccinee effect biases vaccine effectiveness estimates remains unclear. This study investigated how different levels of the healthy vaccinee effect may impact these estimates. Methods: Three national, matched, retrospective cohort studies were conducted on the population of Qatar from February 5, 2020-May 14, 2024, to estimate effectiveness of primary- series and booster vaccinations and of natural infection against infection and reinfection. The studies explored three different scenarios for matching by coexisting conditions, each reflecting a different level of health-status imbalance between vaccinated and unvaccinated individuals. Results: Estimated effectiveness of primary-series and booster vaccinations against infection and against severe, critical, or fatal COVID-19 showed consistent values across the different matching strategies, despite varying hazard ratios for non-COVID-19 deaths. For example, primary-series effectiveness against severe, critical, or fatal COVID-19 was 96.3% (95% CI: 94.5-97.5) when matching by exact coexisting condition types, 94.2% (95% CI: 92.5-95.6) when matching by number of coexisting conditions, and 94.0% (95% CI: 92.3-95.3) with no matching by coexisting conditions. Similar results were observed when the analysis was stratified by the duration of follow-up and for the subgroup of individuals clinically vulnerable to severe COVID-19. Analogous results were found for effectiveness of natural infection against reinfection and against severe, critical, or fatal COVID-19 upon reinfection. Conclusion: The imbalance in health status between vaccinated and unvaccinated individuals in real-world conditions did not introduce a healthy vaccinee bias into the estimated vaccine effectiveness.

  • Open Access

    Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar

    by Layan Sukik, Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Patrick Tang, Mohammad R Hasan, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, et al.

    Background: Accurately assessing SARS-CoV-2 infection severity is essential for understanding the health impact of the infection and evaluating the effectiveness of interventions. This study investigated whether SARS-CoV-2–associated hospitalizations can reliably measure true COVID-19 severity. Methods: The diagnostic accuracy of SARS-CoV-2–associated acute care and ICU hospitalizations as indicators of infection severity was assessed in Qatar from 6 September 2021 to 13 May 2024. WHO criteria for severe, critical, and fatal COVID-19 served as the reference standard. Two indicators were assessed: (1) any SARS-CoV-2–associated hospitalization in acute care or ICU beds and (2) ICU-only hospitalizations. Results: A total of 644 176 SARS-CoV-2 infections were analyzed. The percent agreement between any SARS-CoV-2–associated hospitalization (acute care or ICU) and WHO criteria was 98.7% (95% confidence interval (CI), 98.6–98.7); however, Cohen's kappa was only 0.17 (95% CI, 0.16–0.18), indicating poor agreement. Sensitivity, specificity, PPV, and negative predictive value were 100% (95% CI, 99.6–100), 98.7% (95% CI, 98.6–98.7), 9.7% (95% CI, 9.1–10.3), and 100% (95% CI, 100–100), respectively. For SARS-CoV-2–associated ICU-only hospitalizations, the percent agreement was 99.8% (95% CI, 99.8–99.9), with a kappa of 0.47 (95% CI, 0.44–0.50), indicating fair-to-good agreement. Sensitivity, specificity, PPV, and negative predictive value were 46.6% (95% CI, 43.4–49.9), 99.9% (95% CI, 99.9–99.9), 47.9% (95% CI, 44.6–51.2), and 99.9% (95% CI, 99.9–99.9), respectively. Conclusions: Generic hospital admissions are unreliable indicators of COVID-19 severity, whereas ICU admissions are somewhat more accurate. The findings demonstrate the importance of applying specific, robust criteria—such as WHO criteria—to reduce bias in epidemiological and vaccine effectiveness studies.


  • Open Access

    Assessing Healthy Vaccinee Effect in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar

    by Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: This study investigated the presence of the healthy vaccinee bias in two COVID-19 vaccine effectiveness studies, involving primary series and booster vaccinations, as well as its temporal patterns and variability across different subpopulations, by examining the association between COVID-19 vaccination and non-COVID-19 mortality in Qatar. Methods: Two matched, retrospective cohort studies assessed the incidence of non-COVID-19 death in national cohorts of individuals with a primary series vaccination versus no vaccination (two-dose analysis), and individuals with three-dose (booster) vaccination versus primary series vaccination (three-dose analysis), from January 5, 2021, to April 9, 2024. Results: The adjusted hazard ratio (aHR) for non-COVID-19 death was 0.76 (95% CI: 0.64-0.90) in the two-dose analysis and 0.85 (95% CI: 0.67-1.07) in the three-dose analysis. In the first six months of follow-up in the two-dose analysis, the aHR was 0.35 (95% CI: 0.27-0.46); however, the combined analysis of all subsequent periods showed an aHR of 1.52 (95% CI: 1.19- 1.94). In the first six months of follow-up in the three-dose analysis, the aHR was 0.31 (95% CI: 0.20-0.50); however, the combined analysis of all subsequent periods showed an aHR of 1.37 (95% CI: 1.02-1.85). The overall effectiveness of the primary series and third-dose vaccinations against severe, critical, or fatal COVID-19 was 95.9% (95% CI: 94.0-97.1) and 34.1% (95% CI:-46.4-76.7), respectively. Subgroup analyses showed that the healthy vaccinee bias is pronounced among those aged 50 years and older and among those more clinically vulnerable to severe COVID-19. Conclusion: A strong healthy vaccinee bias was observed in the first six months following vaccination. This bias may have stemmed from a lower likelihood of vaccination among seriously ill, end-of-life individuals, and less mobile elderly populations. Despite this bias, vaccination provided strong protection against severe COVID-19.

  • Open Access

    Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

    by Hiam Chemaitelly, Peter Coyle, Mohamed Ali Ben Kacem, Houssein H. Ayoub, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, et al.

    This study investigated the effectiveness of natural infection in preventing reinfection with the JN.1 variant during a large JN.1 wave in Qatar, using a test-negative case-control study design. The overall effectiveness of previous infection in preventing reinfection with JN.1 was estimated at only 1.8% (95% CI: −9.3-12.6%). This effectiveness demonstrated a rapid decline over time since the previous infection, decreasing from 82.4% (95% CI: 40.9-94.7%) within 3 to less than 6 months after the previous infection to 50.9% (95% CI: −11.8-78.7%) in the subsequent 3 months, and further dropping to 18.3% (95% CI: −34.6-56.3%) in the subsequent 3 months. Ultimately, it reached a negligible level after one year. The findings show that the protection of natural infection against reinfection with JN.1 is strong only among those who were infected within the last 6 months, with variants such as XBB*. However, this protection wanes rapidly and is entirely lost one year after the previous infection. The findings support considerable immune evasion by JN.1.

  • Open Access

    SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

    by Mai A. Mahmoud, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al‐Kanaani, Einas Al‐Kuwari, Andrew Jeremijenko, et al.

    Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and of severe, critical, or fatal COVID‐19 in older adults since pandemic onset.Methods: A national retrospective cohort study was conducted in the population of Qatar aged ≥50 years between February 5, 2020 and June 15, 2023. Adjusted hazard ratios (AHRs) for infection and for severe coronavirus disease 2019 (COVID‐19) outcomes were estimated through Cox regression models.Results: Cumulative incidence was 25.01% (95% confidence interval [CI]: 24.86–25.15%) for infection and 1.59% (95% CI: 1.55–1.64%) for severe, critical, or fatal COVID‐19 after a follow‐up duration of 40.9 months. Risk of infection varied minimally by age and sex but increased significantly with coexisting conditions. Risk of infection was reduced with primary‐series vaccination (AHR: 0.91, 95% CI: 0.90–0.93) and further with first booster vaccination (AHR: 0.75, 95% CI: 0.74–0.77). Risk of severe, critical, or fatal COVID‐19 increased exponentially with age and linearly with coexisting conditions. AHRs for severe, critical, or fatal COVID‐19 were 0.86 (95% CI: 0.7–0.97) for one dose, 0.15 (95% CI: 0.13–0.17) for primary‐series vaccination, and 0.11 (95% CI: 0.08–0.14) for first booster vaccination. Sensitivity analysis restricted to only Qataris yielded similar results.Conclusion: Incidence of severe COVID‐19 in older adults followed a dynamic pattern shaped by infection incidence, variant severity, and population immunity. Age, sex, and coexisting conditions were strong determinants of infection severity. Vaccine protection against severe outcomes showed a dose–response relationship, highlighting the importance of booster vaccination for older adults.


  • Open Access

    History of primary-series and booster vaccination and protection against Omicron reinfection

    by Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Peter V. Coyle, Hadi M. Yassine, Asmaa A. Al Thani, Hebah A. Al-Khatib, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, et al.

    Laboratory evidence suggests a possibility of immune imprinting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the differences in the incidence of SARS-CoV-2 reinfection in a cohort of persons who had a primary Omicron infection, but different vaccination histories using matched, national, retrospective, cohort studies. Adjusted hazard ratio for reinfection incidence, factoring adjustment for differences in testing rate, was 0.43 [95% confidence interval (CI): 0.39 to 0.49] comparing history of two-dose vaccination to no vaccination, 1.47 (95% CI: 1.23 to 1.76) comparing history of three-dose vaccination to two-dose vaccination, and 0.57 (95% CI: 0.48 to 0.68) comparing history of three-dose vaccination to no vaccination. Divergence in cumulative incidence curves increased markedly when the incidence was dominated by BA.4/BA.5 and BA.2.75* Omicron subvariants. The history of primary-series vaccination enhanced immune protection against Omicron reinfection, but history of booster vaccination compromised protection against Omicron reinfection. These findings do not undermine the public health utility of booster vaccination.


  • Open Access

    Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

    by Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Hadi M. Yassine, Asmaa A. Al Thani, Hebah A. Al-Khatib, Mohammad R. Hasan, Zaina Al-Kanaani, et al.


  • Open Access

    Patterns in Repeat Reinfections: Pre and Post Omicron Emergence

    by Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Peter Coyle, Hadi M. Yassine, Asmaa A. Al Thani, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Our understanding of SARS-CoV-2 reinfection patterns remains limited. We conducted a longitudinal study using Qatar’s national SARS-CoV-2 data from February 28, 2020 to June 11, 2023 to investigate incidence of reinfections both prior to and after omicron emergence. The latter analysis excluded individuals with pre-omicron infections. Before omicron introduction, the proportion of incident infections classified as reinfections gradually increased but remained minimal, reaching 1.8% just before omicron emerged. During the first omicron wave, this proportion reached 9.0%, a 5-fold increase. After the conclusion of the first omicron wave, the proportion of incident infections identified as reinfections rapidly increased, reaching 43.3% towards the end of the study. In the pre-omicron era, a total of 3,131 reinfections were documented, of which 99.6% were first reinfections and 0.4% were second reinfections. Meanwhile, a total of 20,962 reinfections were documented after an omicron primary infection of which 99.0% were first reinfections, 1.0% were second reinfections, and 0.01% were third reinfections. Reinfections were rare before omicron’s emergence but became widespread during the omicron era, including among individuals previously infected with omicron. Our findings may indicate accelerated viral evolution in the omicron era aimed at evading population immunity, but with minimal impact on COVID-19 severity, or potentially suggest immune imprinting effects that require further investigation.


  • Open Access

    A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar

    by Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Hebah A. Al-Khatib, Asmaa A. Al Thani, Zaina Al-Kanaani, et al.

    Background This study assessed the evolution of COVID-19 severity and fatality by utilizing rigorous and standardized criteria that were consistently applied throughout the pandemic in Qatar. Methods A national cohort study was conducted on Qataris, using data on COVID-19 acute-care and ICU hospitalizations, as well as severe, critical, and fatal COVID-19 cases classified according to the World Health Organization criteria. Results The cumulative incidence of severe, critical, or fatal COVID-19 after 3.14 years of follow-up was 0.45% (95% CI: 0.43-0.47%). The incidence rate for severe, critical, or fatal COVID-19 throughout the pandemic was 1.43 (95% CI: 1.35-1.50) per 1,000 person-years. In the pre-omicron phase, first omicron wave, and combined phases, it was 2.01 (95% CI: 1.90-2.13), 3.70 (95% CI: 3.25-4.22), and 2.18 (95% CI: 2.07-2.30) per 1,000 person-years, respectively. The post-first omicron phase saw a drastic drop to 0.10 (95% CI: 0.08-0.14) per 1,000 person-years, a 95.4% reduction. Among all severe, critical, and fatal cases, 99.5% occurred during the primary infection. The cumulative incidence of fatal COVID-19 was 0.042% (95% CI: 0.036-0.050%), with an incidence rate of 0.13 (95% CI: 0.11-0.16) per 1,000 person-years. In the post-first omicron phase, the incidence rate of fatal COVID-19 decreased by 90.0% compared to earlier stages. Both severity and fatality exhibited an exponential increase with age and a linear increase with the number of coexisting conditions. Conclusions The conclusion of the first omicron wave was a turning point in the severity of the pandemic. While vaccination and enhanced case management reduced severity gradually, the rapid accumulation of natural immunity during the initial omicron wave appears to have played the crucial role in driving this shift in severity.